We're testing an investigational medication called SP-624 to help reduce depression symptoms. You'll receive either SP-624 or a placebo while being monitored closely by our caring team. This research could lead to better treatment options for people living with depression.
We're conducting a Phase 2 research study to test how well SP-624works for treating major depressive disorder. This is a double-blind study, meaning neither you nor our research team will know which medication you're receiving—this helps us get the most accurate results. Throughout the study, you'll attend regular visits where we'll evaluate your symptoms, monitor your safety, and conduct clinical assessments to understand how you're doing.
Contact us directly:
Phone: +1 657 230 7120
If you completed our previous binge eating study, you're invited to continue your treatment journey with us. This next phase lets you keep accessing medication that may help reduce binge eating episodes, with close medical support every step of the way. You'll be part of important research that helps us understand how to best support people like you long-term.
Learn MoreAre you or a loved one experiencing agitation related to Alzheimer's disease? This research study is testing a new oral medication called BMS-986368 to help reduce agitation and improve quality of life. We're looking for participants ages 55-90 to join us in this important work.
Learn MoreLiving with ulcerative colitis while managing your weight can feel overwhelming. We're testing a combination approach that may help calm your UC symptoms while supporting meaningful weight loss—giving you the chance to feel better in two important ways.
Learn More